Table 4.
Multivariable competing risk analyses predicting the risk of overall recurrence and CSM in patients treated with radical cystectomy after propensity matching.
| Variables | Overall Recurrence | CSM | ||
|---|---|---|---|---|
| HR (CI 95%) | p Value | HR (CI 95%) | p Value | |
| Gender (male vs. female) | 1.09 (0.80–1.48) | 0.6 | 1.23 (0.91–1.67) | 0.1 |
| Age, years | 1.00 (0.99–1.01) | 0.5 | 1.01 (0.99–1.02) | 0.09 |
| RARC approach | 0.76 (0.39–1.47) | 0.4 | 1.34 (0.49–2.36) | 0.8 |
| pT stage | ||||
| pT0-1 | Ref | Ref | Ref | Ref |
| pT2 | 1.21 (0.77–1.90) | 0.3 | 1.34 (0.84–2.15) | 0.2 |
| pT3-4 | 1.57 (1.04–2.37) | 0.03 | 2.17 (1.40–3.35) | <0.001 |
| pN+ | 1.43 (1.05–1.94) | 0.02 | 2.33 (1.71–3.16) | <0.001 |
| Nodes removed | 0.99 (0.98–1.00) | 0.3 | 0.98 (0.97–0.99) | 0.01 |
| High grade vs. low | 3.20 (1.55–6.59) | 0.002 | 3.60 (1.62–7.98) | 0.002 |
| LVI | 1.85 (1.37–2.49) | <0.001 | 1.27 (0.96–1.70) | 0.09 |
| Positive surgical margins | 1.12 (0.74–1.69) | 0.5 | 1.30 (0.84–2.01) | 0.2 |
| Neoadjuvant chemotherapy | 1.96 (1.51–2.54) | <0.001 | 1.34 (1.02–1.76) | 0.03 |
| Adjuvant chemotherapy | 1.29 (0.94–1.77) | 0.1 | 0.77 (0.56–1.06) | 0.1 |
CSM: cancer specific mortality, HR: Hazard ratio, CI: confidence interval, RARC: robotic assisted radical cystectomy, LVI: lymphovascular invasion.